King & Spalding advised medical device maker Zimmer Holdings, Inc., on the regulatory aspects of the company’s $13.4 Billion acquisition of Biomet, Inc., in a deal that will make Zimmer the second-largest company in the muscle and orthopaedic injury treatment market. The deal is expected to close in the first quarter of 2015.
The King & Spalding FDA and life sciences regulatory team involved in the transaction consisted of partners Mark S. Brown and Edward M. Basile, consultant Steven Niedelman and associate Jessica M. Ringel, all in the firm’s Washington, D.C., office.
Warsaw, Indiana-based Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants and related surgical products. Biomet is a manufacturer of surgical and non-surgical products used primarily by orthopaedic surgeons and other musculoskeletal medical specialists.
